Tallinn 10:00-14:00
Riga 10:00-14:00
Vilnius 10:00-14:00
Moscow 09:30-17:45
Stockholm 10:00-18:20
Helsinki 10:00-18:20
ETFs 16:30-23:00

All times: GMT +2
2009-01-05 23:59:02
EUR/USD 0.7186
EUR/LVL 1.4144
EUR/LTL 0.2896
EUR/EEK 0.0639
EUR/SEK 0.0924
EUR/RUB 0.0255
Indices: / OMXR 0.00% / OMXV 0.00% / OMXT 0.00% / OMXS30 0.00% / OMXH25 0.00% / MICEX 0.00%                     Stocks: VTBR 0.00% / OMXV 0.00% / OMXR 0.00% / EEH1T 0.00% / GAZP 0.00% / VTBR 0.00% / OMXV 0.00% / OMXR 0.00% / EEH1T 0.00% / GAZP 0.00%                     Porfolios: StraterS 0.00% / koncik 0.00% / Laime 0.00% / Life 0.00% / RIX 0.00%
 

HEX (Helsinki) Market Overviews

Helsinki Stock Market Overview
14/11/2005-18/11/2005


The November 18, the big day for all Latvians, has passed and life is going further. Riga Stock Exchange was not warking that Friday, because of Day of Independency of Latvia. Other stock markets were rallying on the full throtle and showed some surprising changes, while most of the stocks were fluctuating insignificantly.

Ruukki Group Oyj (RUG1V), has nice days this decade. As well as two weeks ago, when after the interim report share price escalated by 16%, this week the monthly report caused further increase by 16,67%. As the report was issued in Finnish on Friday, particular reasons of such an increase are still to be discovered. Some clues might be found in overall positive development of the company this year. New factory in Russia, major contract with Japanese company give hopes to investors.

Tekla Corporation (TLA1V), international software company. Tekla's Board of Directors on 17.11 confirmed the schedule of the return of capital. The final amount of Tekla shares entitled to the return of capital is 22,516,600 and the payment is 0.55 euros per share. The return of capital thus amounts totally to 12,384,130 euros. This message resulted a plunge of share price by 13,66%.

Orion Corporation (ORNBS), Finnish pharmaceutical giant, experienced approximately 24% decrease in all 3 kinds of shares. On the November 16th research on its product Levosimendan has finished and showed that levosimendan (Simdax®) does not give any statistically essential improvements to health. The study did not meet its primary endpoint of a statistically significant reduction in 180-day all-cause mortality. The data were presented at the late-breaking clinical trials session of the American Heart Association 2005 annual meeting. As this medicament is used in more then 40 countries, disappointment of investors is quite natural.

By Boriss Kuzmins
Dmitrisj Jazikovs